Cancer pharmacogenomics: Current and future applications

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1603, Issue 2, 2003, Pages 99-111

  Watters, James W ^a   McLeod, Howard L ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

Cancer; Genetic; Genomic; Microarray; Molecular therapeutic; Pharmacogenetic; Pharmacogenomic; Polymorphism

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DRUG METABOLIZING ENZYME; FLUOROURACIL; IRINOTECAN; MERCAPTOPURINE; OXALIPLATIN; THIOPURINE METHYLTRANSFERASE;

CANCER CHEMOTHERAPY; DRUG DISPOSITION; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOME; HUMAN; MEDICAL TECHNOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SEX DIFFERENTIATION; TREATMENT OUTCOME;

EID: 0037451804     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-419X(03)00003-9     Document Type: Review

References (88)

1. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 286:1999;487-491.
2. Sargent D.J., Niedzwiecki D., O'Connell M.J., Schilsky R.L. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N. Engl. J. Med. 345:2001;144-145. (discussion 146).
3. Rothenberg M.L., Meropol N.J., Poplin E.A., Van Cutsem E., Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J. Clin. Oncol. 19:2001;3801-3807.
4. Evans W.E., Johnson J.A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu. Rev. Genomics Hum. Genet. 2:2001;9-39.
5. McLeod H.L., Evans W.E. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu. Rev. Pharmacol. Toxicol. 41:2001;101-121.
6. Phillips K., Veenstra D., Oren E., Lee J., Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA. 286:2001;2270-2279.
7. McLeod H.L., Krynetski E.Y., Relling M.V., Evans W.E. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia. 14:2000;567-572.
8. Krynetski E.Y., Evans W.E. Pharmacogenetics of cancer therapy: getting personal. Am. J. Hum. Genet. 63:1998;11-16.
9. Weinshilboum R.M., Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32:1980;651-662.
10. McLeod H.L., Relling M.V., Liu Q., Pui C.H., Evans W.E. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood. 85:1995;1897-1902.
11. Krynetski E.Y., Schuetz J.D., Galpin A.J., Pui C.H., Relling M.V., Evans W.E. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl. Acad. Sci. U. S. A. 92:1995;949-953.
12. Tai H.L., Krynetski E.Y., Yates C.R., Loennechen T., Fessing M.Y., Krynetskaia N.F., Evans W.E. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet. 58:1996;694-702.
13. Otterness D., Szumlanski C., Lennard L., Klemetsdal B., Aarbakke J., Park-Hah J.O., Iven H., Schmiegelow K., Branum E., O'Brien J., Weinshilboum R. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin. Pharmacol. Ther. 62:1997;60-73.
14. Yates C.R., Krynetski E.Y., Loennechen T., Fessing M.Y., Tai H.L., Pui C.H., Relling M.V., Evans W.E. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126:1997;608-614.
15. Tai H.L., Krynetski E.Y., Schuetz E.G., Yanishevski Y., Evans W.E. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl. Acad. Sci. U. S. A. 94:1997;6444-6449.
16. Hon Y.Y., Fessing M.Y., Pui C.H., Relling M.V., Krynetski E.Y., Evans W.E. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum. Mol. Genet. 8:1999;371-376.
17. Lennard L., VanLoon J.A., Weinshilboum R.M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 46:1989;149-154.
18. Evans W.E., Horner M., Chu Y.Q., Kalwinsky D., Roberts W.M. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J. Pediatr. 119:1991;985-989.
19. Black A.J., McLeod H.L., Capell H.A., Powrie R.H., Matowe L.K., Pritchard S.C., Collie-Duguid E.S., Reid D.M. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med. 129:1998;716-718.
20. Relling M.V., Hancock M.L., Rivera G.K., Sandlund J.T., Ribeiro R.C., Krynetski E.Y., Pui C.H., Evans W.E. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl. Cancer Inst. 91:1999;2001-2008.
21. McLeod H.L., Coulthard S., Thomas A.E., Pritchard S.C., King D.J., Richards S.M., Eden O.B., Hall A.G., Gibson B.E. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br. J. Haematol. 105:1999;696-700.
22. McLeod H.L., Siva C. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics. 3:2002;89-98.
23. Etienne M.C., Lagrange J.L., Dassonville O., Fleming R., Thyss A., Renee N., Schneider M., Demard F., Milano G. Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 12:1994;2248-2253.
24. Lu Z., Zhang R., Diasio R.B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 53:1993;5433-5438.
25. Johnson M.R., Hageboutros A., Wang K., High L., Smith J.B., Diasio R.B. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin. Cancer Res. 5:1999;2006-2011.
26. Diasio R.B., Beavers T.L., Carpenter J.T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Invest. 81:1988;47-51.
27. Diasio R.B. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology (Huntingt.). 15:2001;21-26. (discussion 27).
28. van Kuilenburg A.B., Muller E.W., Haasjes J., Meinsma R., Zoetekouw L., Waterham H.R., Baas F., Richel D.J., van Gennip A.H. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin. Cancer Res. 7:2001;1149-1153.
29. Innocenti F., Ratain M.J. Update on pharmacogenetics in cancer chemotherapy. Eur. J. Cancer. 38:2002;639-644.
30. Wei X., McLeod H.L., McMurrough J., Gonzalez F.J., Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98:1996;610-615.
31. McLeod H.L., Collie-Duguid E.S., Vreken P., Johnson M.R., Wei X., Sapone A., Diasio R.B., Fernandez-Salguero P., van Kuilenberg A.B., van Gennip A.H., Gonzalez F.J. Nomenclature for human DPYD alleles. Pharmacogenetics. 8:1998;455-459.
32. Gonzalez F.J., Fernandez-Salguero P. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol. Sci. 16:1995;325-327.
33. Ridge S.A., Sludden J., Brown O., Robertson L., Wei X., Sapone A., Fernandez-Salguero P.M., Gonzalez F.J., Vreken P., van Kuilenburg A.B., van Gennip A.H., McLeod H.L. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br. J. Clin. Pharmacol. 46:1998;151-156.
34. Ridge S.A., Sludden J., Wei X., Sapone A., Brown O., Hardy S., Canney P., Fernandez-Salguero P., Gonzalez F.J., Cassidy J., McLeod H.L. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br. J. Cancer. 77:1998;497-500.
35. Raida M., Schwabe W., Hausler P., Van Kuilenburg A.B., Van Gennip A.H., Behnke D., Hoffken K. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin. Cancer Res. 7:2001;2832-2839.
36. Collie-Duguid E.S., Etienne M.C., Milano G., McLeod H.L. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics. 10:2000;217-223.
37. Johnston P.G., Lenz H.J., Leichman C.G., Danenberg K.D., Allegra C.J., Danenberg P.V., Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55:1995;1407-1412.
38. Leichman C.G., Lenz H.J., Leichman L., Danenberg K., Baranda J., Groshen S., Boswell W., Metzger R., Tan M., Danenberg P.V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 15:1997;3223-3229.
39. Kaneda S., Takeishi K., Ayusawa D., Shimizu K., Seno T., Altman S. Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA. Nucleic Acids Res. 15:1987;1259-1270.
40. Horie N., Aiba H., Oguro K., Hojo H., Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20:1995;191-197.
41. Marsh S., Ameyaw M.M., Githang'a J., Indalo A., Ofori-Adjei D., McLeod H.L. Novel thymidylate synthase enhancer region alleles in African populations. Human Mutat. 16:2000;528.
42. Luo H.R., Lu X.M., Yao Y.G., Horie N., Takeishi K., Jorde L.B., Zhang Y.P. Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem. Genet. 40:2002;41-51.
43. Pullarkat S.T., Stoehlmacher J., Ghaderi V., Xiong Y.P., Ingles S.A., Sherrod A., Warren R., Tsao-Wei D., Groshen S., Lenz H.J. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1:2001;65-70.
44. Villafranca E., Okruzhnov Y., Dominguez M.A., Garcia-Foncillas J., Azinovic I., Martinez E., Illarramendi J.J., Arias F., Martinez Monge R., Salgado E., Angeletti S., Brugarolas A. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 19:2001;1779-1786.
45. Marsh S., McKay J.A., Cassidy J., McLeod H.L. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J. Oncol. 19:2001;383-386.
46. Gupta E., Lestingi T.M., Mick R., Ramirez J., Vokes E.E., Ratain M.J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54:1994;3723-3725.
47. Iyer L., King C.D., Whitington P.F., Green M.D., Roy S.K., Tephly T.R., Coffman B.L., Ratain M.J. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 101:1998;847-854.
48. Iyer L., Hall D., Das S., Mortell M.A., Ramirez J., Kim S., DiRienzo A., Ratain M.J. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 65:1999;576-582.
49. Fisher M.B., Vandenbranden M., Findlay K., Burchell B., Thummel K.E., Hall S.D., Wrighton S.A. Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics. 10:2000;727-739.
50. Beutler E., Gelbart T., Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl. Acad. Sci. U. S. A. 95:1998;8170-8174.
51. Iyer L., Das S., Janisch L., Wen M., Ramirez J., Karrison T., Fleming G.F., Vokes E.E., Schilsky R.L., Ratain M.J. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2:2002;43-47.
52. Ando Y., Saka H., Ando M., Sawa T., Muro K., Ueoka H., Yokoyama A., Saitoh S., Shimokata K., Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60:2000;6921-6926.
53. Reardon J.T., Sancar A. Dizdaroglu M., Karakaya A. Advances in DNA Damage and Repair. 1998;377-393 Plenum, New York.
54. Johnson N.P., Hoeschele J.D., Rahn R.O. Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA. Chem.-Biol. Interact. 30:1980;151-169.
55. Park D.J., Stoehlmacher J., Zhang W., Tsao-Wei D.D., Groshen S., Lenz H.J. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 61:2001;8654-8658.
56. Lunn R.M., Helzlsouer K.J., Parshad R., Umbach D.M., Harris E.L., Sanford K.K., Bell D.A. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis. 21:2000;551-555.
57. Spitz M.R., Wu X., Wang Y., Wang L.E., Shete S., Amos C.I., Guo Z., Lei L., Mohrenweiser H., Wei Q. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 61:2001;1354-1357.
58. Stoehlmacher J., Ghaderi V., Iobal S., Groshen S., Tsao-Wei D., Park D., Lenz H.J. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res. 21:2001;3075-3079.
59. Lunn R.M., Langlois R.G., Hsieh L.L., Thompson C.L., Bell D.A. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res. 59:1999;2557-2561.
60. Zhang K., Mack P., Wong K.P. Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int. J. Oncol. 12:1998;871-882.
61. Board P.G., Baker R.T., Chelvanayagam G., Jermiin L.S. Zeta, a novel class of glutathione transferases in a range of species from plants to humans. Biochem. J. 328:1997;929-935.
62. Chao C.C., Huang Y.T., Ma C.M., Chou W.Y., Lin-Chao S. Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line. Mol. Pharmacol. 41:1992;69-75.
63. Stoehlmacher J., Park D.J., Zhang W., Groshen S., Tsao-Wei D.D., Yu M.C., Lenz H.J. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl. Cancer. Inst. 94:2002;936-942.
64. Watson M.A., Stewart R.K., Smith G.B., Massey T.E., Bell D.A. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis. 19:1998;275-280.
65. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., Bloomfield C.D., Lander E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 286:1999;531-537.
66. Yeoh E.J., Ross M.E., Shurtleff S.A., Williams W.K., Patel D., Mahfouz R., Behm F.G., Raimondi S.C., Relling M.V., Patel A., Cheng C., Campana D., Wilkins D., Zhou X., Li J., Liu H., Pui C.H., Evans W.E., Naeve C., Wong L., Downing J.R. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 1:2002;133-143.
67. Okutsu J., Tsunoda T., Kaneta Y., Katagiri T., Kitahara O., Zembutsu H., Yanagawa R., Miyawaki S. Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol. Cancer Ther. 1:2002;1035-1042.
68. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L., Marti G.E., Moore T., Hudson J. Jr., Lu L., Lewis D.B., Tibshirani R., Sherlock G., Chan W.C., Greiner T.C., Weisenburger D.D., Armitage J.O., Warnke R., Staudt L.M.et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:2000;503-511.
69. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., Gascoyne R.D., Muller-Hermelink H.K., Smeland E.B., Giltnane J.M., Hurt E.M., Zhao H., Averett L., Yang L., Wilson W.H., Jaffe E.S., Simon R., Klausner R.D., Powell J., Duffey P.L., Longo D.L., Greiner T.C., Weisenburger D.D., Sanger W.G., Dave B.J., Lynch J.C., Vose J., Armitage J.O., Montserrat E., Lopez-Guillermo A., Grogan T.M., Miller T.P., LeBlanc M., Ott G., Kvaloy S., Delabie J., Holte H., Krajci P., Stokke T., Staudt L.M. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:2002;1937-1947.
70. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536.
71. Caldas C., Aparicio S.A. The molecular outlook. Nature. 415:2002;484-485.
72. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lonning P., Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 98:2001;10869-10874.
73. Silver L.M. Mouse Genetics. 1995;Oxford Univ. Press, New York.
74. Haston C.K., Wang M., Dejournett R.E., Zhou X., Ni D., Gu X., King T.M., Weil M.M., Newman R.A., Amos C.I., Travis E.L. Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. Hum. Mol. Genet. 11:2002;1855-1863.
75. Zhang Y., Lefort J., Kearsey V., Lapa e Silva J.R., Cookson W.O., Vargaftig B.B. A genome-wide screen for asthma-associated quantitative trait loci in a mouse model of allergic asthma. Hum. Mol. Genet. 8:1999;601-605.
76. Haston C.K., Zhou X., Gumbiner-Russo L., Irani R., Dejournett R., Gu X., Weil M., Amos C.I., Travis E.L. Universal and radiation-specific loci influence murine susceptibility to radiation-induced pulmonary fibrosis. Cancer Res. 62:2002;3782-3788.
77. Kleeberger S.R., Levitt R.C., Zhang L.Y., Longphre M., Harkema J., Jedlicka A., Eleff S.M., DiSilvestre D., Holroyd K.J. Linkage analysis of susceptibility to ozone-induced lung inflammation in inbred mice. Nat. Genet. 17:1997;475-478.
78. Ohtsuka Y., Brunson K.J., Jedlicka A.E., Mitzner W., Clarke R.W., Zhang L.Y., Eleff S.M., Kleeberger S.R. Genetic linkage analysis of susceptibility to particle exposure in mice. Am. J. Respir. Cell Mol. Biol. 22:2000;574-581.
79. Piguet P.F., Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur. Respir. J. 7:1994;515-518.
80. Katsuma S., Nishi K., Tanigawara K., Ikawa H., Shiojima S., Takagaki K., Kaminishi Y., Suzuki Y., Hirasawa A., Ohgi T., Yano J., Murakami Y., Tsujimoto G. Molecular monitoring of bleomycin-induced pulmonary fibrosis by cDNA microarray-based gene expression profiling. Biochem. Biophys. Res. Commun. 288:2001;747-751.
81. Nadeau J.H., Frankel W.N. The roads from phenotypic variation to gene discovery: mutagenesis versus QTLs. Nat. Genet. 25:2000;381-384.
82. Darvasi A. Experimental strategies for the genetic dissection of complex traits in animal models. Nat. Genet. 18:1998;19-24.
83. Nagase T., Uozumi N., Ishii S., Kita Y., Yamamoto H., Ohga E., Ouchi Y., Shimizu T. A pivotal role of cytosolic phospholipase A(2) in bleomycin-induced pulmonary fibrosis. Nat. Med. 8:2002;480-484.
84. Zhao J., Shi W., Wang Y.L., Chen H., Bringas P. Jr., Datto M.B., Frederick J.P., Wang X.F., Warburton D. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. Physiol., Lung Cell Mol. Physiol. 282:2002;L585-L593.
85. Peters-Golden M., Bailie M., Marshall T., Wilke C., Phan S.H., Toews G.B., Moore B.B. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am. J. Respir. Crit. Care Med. 165:2002;229-235.
86. Okazaki T., Nakao A., Nakano H., Takahashi F., Takahashi K., Shimozato O., Takeda K., Yagita H., Okumura K. Impairment of bleomycin-induced lung fibrosis in CD28-deficient mice. J. Immunol. 167:2001;1977-1981.
87. Chen E.S., Greenlee B.M., Wills-Karp M., Moller D.R. Attenuation of lung inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin. Am. J. Respir. Cell Mol. Biol. 24:2001;545-555.
88. Kawakami K., Omura K., Kanehira E., Watanabe Y. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res. 19:1999;3249-3252.